Literature DB >> 26848785

Lysyl Oxidase Isoforms and Potential Therapeutic Opportunities for Fibrosis and Cancer.

Philip C Trackman1.   

Abstract

INTRODUCTION: The lysyl oxidase family of enzymes is classically known as being required for connective tissue maturation by oxidizing lysine residues in elastin and lysine and hydroxylysine residues in collagen precursors. The resulting aldehydes then participate in cross-link formation, which is required for normal connective tissue integrity. These enzymes have biological functions that extend beyond this fundamental biosynthetic role, with contributions to angiogenesis, cell proliferation, and cell differentiation. Dysregulation of lysyl oxidases occurs in multiple pathologies including fibrosis, primary and metastatic cancers, and complications of diabetes in a variety of tissues. AREAS COVERED: This review summarizes the major findings of novel roles for lysyl oxidases in pathologies, and highlights some of the potential therapeutic approaches that are in development and which stem from these new findings. EXPERT OPINION: Fundamental questions remain regarding the mechanisms of novel biological functions of this family of proteins, and regarding functions that are independent of their catalytic enzyme activity. However, progress is underway in the development of isoform-specific pharmacologic inhibitors, potential therapeutic antibodies and gaining an increased understanding of both tumor suppressor and metastasis promotion activities. Ultimately, this is likely to lead to novel therapeutic agents.

Entities:  

Keywords:  Cancer; copper amine oxidases; fibrosis; lysyl oxidase propeptide; lysyl oxidases; lysyl tyrosylquinone

Mesh:

Substances:

Year:  2016        PMID: 26848785      PMCID: PMC4988797          DOI: 10.1517/14728222.2016.1151003

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  169 in total

1.  Lysyl oxidase-like-2 (LOXL2) is a major isoform in chondrocytes and is critically required for differentiation.

Authors:  Mussadiq Iftikhar; Paola Hurtado; Manish V Bais; Nate Wigner; Danielle N Stephens; Louis C Gerstenfeld; Philip C Trackman
Journal:  J Biol Chem       Date:  2010-11-11       Impact factor: 5.157

2.  Comparative sensitivities of purified preparations of lysyl oxidase and other amine oxidases to active site-directed enzyme inhibitors.

Authors:  S S Tang; C O Chichester; H M Kagan
Journal:  Connect Tissue Res       Date:  1989       Impact factor: 3.417

3.  Lysyl oxidase-like-2 promotes tumour angiogenesis and is a potential therapeutic target in angiogenic tumours.

Authors:  Shelly Zaffryar-Eilot; Derek Marshall; Tali Voloshin; Avinoam Bar-Zion; Rhyannon Spangler; Ofra Kessler; Haben Ghermazien; Vera Brekhman; Edith Suss-Toby; Dan Adam; Yuval Shaked; Victoria Smith; Gera Neufeld
Journal:  Carcinogenesis       Date:  2013-07-04       Impact factor: 4.944

4.  The Ras signaling inhibitor LOX-PP interacts with Hsp70 and c-Raf to reduce Erk activation and transformed phenotype of breast cancer cells.

Authors:  Seiichi Sato; Philip C Trackman; Joni M Mäki; Johanna Myllyharju; Kathrin H Kirsch; Gail E Sonenshein
Journal:  Mol Cell Biol       Date:  2011-05-02       Impact factor: 4.272

5.  Characterization of the native lysine tyrosylquinone cofactor in lysyl oxidase by Raman spectroscopy.

Authors:  S X Wang; N Nakamura; M Mure; J P Klinman; J Sanders-Loehr
Journal:  J Biol Chem       Date:  1997-11-14       Impact factor: 5.157

6.  Disruption of the blood-aqueous barrier and lens abnormalities in mice lacking lysyl oxidase-like 1 (LOXL1).

Authors:  Janey L Wiggs; Basil Pawlyk; Edward Connolly; Michael Adamian; Joan W Miller; Louis R Pasquale; Ramez I Haddadin; Cynthia L Grosskreutz; Douglas J Rhee; Tiansen Li
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

7.  Matrix cross-linking lysyl oxidases are induced in response to myocardial infarction and promote cardiac dysfunction.

Authors:  José González-Santamaría; María Villalba; Oscar Busnadiego; Marina M López-Olañeta; Pilar Sandoval; Jessica Snabel; Manuel López-Cabrera; Janine T Erler; Roeland Hanemaaijer; Enrique Lara-Pezzi; Fernando Rodríguez-Pascual
Journal:  Cardiovasc Res       Date:  2015-08-10       Impact factor: 10.787

8.  Lysyl oxidase promotes epithelial-to-mesenchymal transition during paraquat-induced pulmonary fibrosis.

Authors:  Jinfeng Wang; Yong Zhu; Jiuting Tan; Xiaoxiao Meng; Hui Xie; Ruilan Wang
Journal:  Mol Biosyst       Date:  2016-02

9.  Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells.

Authors:  Peter Hollosi; Jana K Yakushiji; Keith S K Fong; Katalin Csiszar; Sheri F T Fong
Journal:  Int J Cancer       Date:  2009-07-15       Impact factor: 7.396

10.  LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition.

Authors:  Eva P Cuevas; Gema Moreno-Bueno; Giacomo Canesin; Vanesa Santos; Francisco Portillo; Amparo Cano
Journal:  Biol Open       Date:  2014-02-15       Impact factor: 2.422

View more
  33 in total

Review 1.  Functional importance of lysyl oxidase family propeptide regions.

Authors:  Philip C Trackman
Journal:  J Cell Commun Signal       Date:  2017-10-30       Impact factor: 5.782

2.  Pseudohypoxic HIF pathway activation dysregulates collagen structure-function in human lung fibrosis.

Authors:  Christopher J Brereton; Liudi Yao; Elizabeth R Davies; Yilu Zhou; Milica Vukmirovic; Joseph A Bell; Siyuan Wang; Robert A Ridley; Lareb S N Dean; Orestis G Andriotis; Franco Conforti; Lennart Brewitz; Soran Mohammed; Timothy Wallis; Ali Tavassoli; Rob M Ewing; Aiman Alzetani; Benjamin G Marshall; Sophie V Fletcher; Philipp J Thurner; Aurelie Fabre; Naftali Kaminski; Luca Richeldi; Atul Bhaskar; Christopher J Schofield; Matthew Loxham; Donna E Davies; Yihua Wang; Mark G Jones
Journal:  Elife       Date:  2022-02-21       Impact factor: 8.713

3.  Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer.

Authors:  Fernando Salvador; Alberto Martin; Celia López-Menéndez; Gema Moreno-Bueno; Vanesa Santos; Alberto Vázquez-Naharro; Patricia G Santamaria; Saleta Morales; Pierre R Dubus; Laura Muinelo-Romay; Rafael López-López; Jason C Tung; Valerie M Weaver; Francisco Portillo; Amparo Cano
Journal:  Cancer Res       Date:  2017-07-18       Impact factor: 12.701

4.  Fibronectin has multifunctional roles in posterior capsular opacification (PCO).

Authors:  Mahbubul H Shihan; Mallika Kanwar; Yan Wang; Erin E Jackson; Adam P Faranda; Melinda K Duncan
Journal:  Matrix Biol       Date:  2020-03-12       Impact factor: 11.583

Review 5.  Signalling pathways involved in hypoxia-induced renal fibrosis.

Authors:  Minna Liu; Xiaoxuan Ning; Rong Li; Zhen Yang; Xiaoxia Yang; Shiren Sun; Qi Qian
Journal:  J Cell Mol Med       Date:  2017-01-18       Impact factor: 5.310

6.  LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway.

Authors:  Eva P Cuevas; Pilar Eraso; María J Mazón; Vanesa Santos; Gema Moreno-Bueno; Amparo Cano; Francisco Portillo
Journal:  Sci Rep       Date:  2017-03-23       Impact factor: 4.379

7.  Lysyl oxidase-like 3 is required for melanoma cell survival by maintaining genomic stability.

Authors:  Patricia G Santamaría; Alfredo Floristán; Bárbara Fontanals-Cirera; Alberto Vázquez-Naharro; Vanesa Santos; Saleta Morales; Lourdes Yuste; Héctor Peinado; Antonio García-Gómez; Francisco Portillo; Eva Hernando; Amparo Cano
Journal:  Cell Death Differ       Date:  2017-12-11       Impact factor: 15.828

8.  Overhydroxylation of Lysine of Collagen Increases Uterine Fibroids Proliferation: Roles of Lysyl Hydroxylases, Lysyl Oxidases, and Matrix Metalloproteinases.

Authors:  Marwa Kamel; Mohamed Wagih; Gokhan S Kilic; Concepcion R Diaz-Arrastia; Mohamed A Baraka; Salama A Salama
Journal:  Biomed Res Int       Date:  2017-09-10       Impact factor: 3.411

9.  Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway.

Authors:  Xiaoying Hou; Hongzhi Du; Xingping Quan; Lei Shi; Qianqian Zhang; Yao Wu; Yang Liu; Jing Xiao; Yong Li; Ligong Lu; Xun Ai; Meixiao Zhan; Shengtao Yuan; Li Sun
Journal:  Front Pharmacol       Date:  2018-02-08       Impact factor: 5.810

10.  Evaluation of Fluorine-18-Labeled α1(I)-N-Telopeptide Analogs as Substrate-Based Radiotracers for PET Imaging of Melanoma-Associated Lysyl Oxidase.

Authors:  Manuela Kuchar; Christin Neuber; Birgit Belter; Ralf Bergmann; Jens Lenk; Robert Wodtke; Torsten Kniess; Jörg Steinbach; Jens Pietzsch; Reik Löser
Journal:  Front Chem       Date:  2018-04-26       Impact factor: 5.221

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.